Press Releases

Year

May 25, 2021

Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Healthcare Conference 2021

BRIDGEWATER, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn,

May 13, 2021

Osmotica Pharmaceuticals plc Reports First Quarter 2021 Results and Provides Business Update

First quarter 2021 total revenue of $23.9 million RVL Pharmaceuticals’ Upneeq wins 2021 MedTech Breakthrough Award; gains recognition as outstanding health and medical technology product Upneeq sales trend higher, exhibiting strong sequential growth Strategic asset review continues; non-core asset

May 12, 2021

Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference

BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the

May 10, 2021

RVL Pharmaceuticals Upneeq® Wins 2021 MedTech Breakthrough Award

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies BRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company,

May 7, 2021

Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021

BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial results on Thursday, May 13, 2021, after the

March 30, 2021

Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update

Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million , respectively Received FDA approval and subsequently introduced Upneeq ® (oxymetazoline hydrochloride ophthalmic solution, 0.1%), the first therapeutic for treatment of acquired ptosis in adults Established Upneeq

March 24, 2021

Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021

BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 30,

March 3, 2021

Osmotica to Present at Barclays Global Healthcare Conference 2021

BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at

February 18, 2021

Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference

BRIDGEWATER, N.J. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and Andrew Einhorn , Chief Financial Officer, will present at

February 1, 2021

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) AMENDMENT The Form 8.1(a) dealings disclosure announcement made on January 27, 2020 contained a typographical error in that it referred to dealings in 'relevant securities' by Gregory L.

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investor Relations

News

Press Releases

Press Releases

Press Releases